Tempest Therapeutics Inc. (TPST)
7.89
0.00 (0.00%)
At close: Apr 24, 2025, 3:59 PM
8.05
1.96%
After-hours: Apr 24, 2025, 04:05 PM EDT
0.00% (1D)
| Bid | 7.65 |
| Market Cap | 27.79M |
| Revenue (ttm) | 486K |
| Net Income (ttm) | -41.84M |
| EPS (ttm) | -19.5 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -4.63 |
| Analyst | Hold |
| Ask | 8.13 |
| Volume | 36,268 |
| Avg. Volume (20D) | 62,804 |
| Open | 7.99 |
| Previous Close | 7.89 |
| Day's Range | 7.65 - 8.23 |
| 52-Week Range | 5.36 - 49.27 |
| Beta | -2.28 |
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops T...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 12, 2012
Employees 24
Stock Exchange NASDAQ
Ticker Symbol TPST
Website https://www.tempesttx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for TPST stock is "Hold." The 12-month stock price forecast is $16, which is an increase of 102.66% from the latest price.
Stock Forecasts5 months ago
-10.47%
Tempest Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
8 months ago
+30.25%
Tempest Therapeutics shares are trading higher after the company announced feedback from its end-of-Phase 2 meeting with the FDA for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.
